Next Phase Newsletter

The firm is a global investment platform specialized in the healthcare & nutrition sector. The firm is operating since 2010 as a multi-stage investment manager, dedicated to evidence-based investment in companies that are developing superior products and services within the healthcare, life science and nutrition market segments. The flexibility of its strategy will allow the firm to not only provide private funding for promising venture companies, but also operate on cross-over financings, IPOs, and offer significant equity financing to fast-growing and profitable companies within the space when they get more established. In 2020, the firm launched the a Europe Venture Fund supported by two family holdings, enjoying privileged access to sector expertise and industrial network within key segment of the Health & Nutrition market, globally. The allocation in venture capital ranges from €5M to €7M ($6M to $8M) per company. The firm invests in Europe, Israel, North America and Middle-East.

The firm is primarily focused on 4 target investments areas :

– Life Science Tools & Diagnostics: Synthetic Biology; Point of Care Solutions; High Value Diagnostics; Life science Tools; Software, system integration & data mngt; New Imaging Solutions.

– Contract Manufacturing & Pharma services: Regulatory & Compliance; Bio-Statistics & Data Analytics; Pharma / API Development & Supply; Contract Development & Manufacturing; Research/ Drug Screening Services; Clinical Trial Design & Monitoring.

– Therapeutic Intervention & Patient Management Services: Infectious Diseases; Orphan Diseases; Respiratory Disorders; Ophthalmology; Home care & Remote patient monitoring.

– Preventive Medicine and Nutrition: Medical food, Probiotics & Nutraceuticals; Food Tracking & Safety; Plant Science & Crop protection; Novel Ingredient & Alternative Proteins; Animal health & nutrition; Novel Farming & Food processing. The firm actively supports entrepreneurs and companies that bring differentiated solutions to unmet medical needs and improve access to high-value products and services.

The firm has 3 principles that guide their investments:

– Invest in people first. The firm is looking for exceptional teams with great integrity, passion and shared vision about what business model to build or expand.

– Back differentiated products and services capable of addressing poorly served clinical needs with the potential to generate substantial revenues in attractive segments of the healthcare market.

– Bring added-value to support great companies globally. The firm’s team must be convinced that its distinctive experience, sector insights and international relationships can materially help entrepreneurs succeed. The firm is performing both growth equity and venture capital investments, therefore the firm primarily interested in small / mid-size companies at different stages of development and could consider investments in public companies. The firm invests in both revenue-generating and pre-revenue companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a pharmaceutical company established in 1997 and is headquartered in California. The firm is the wholly-owned subsidiary of a global pharmaceutical company with headquarters in Japan, that has been in operation since 1848. The company is one of the world’s largest patch manufacturers. The firm is focused on developing innovative products in CNS, oncology, and pain management. In particular, the firm has established a strong global presence in transdermal patch products. The company has several products on the market, including a topical, transdermal patch for post-herpetic neuralgia that provides analgesia to affected nerves and relieve pain. Another product is an injection used for the treatment of cancer, and is the first non-alcohol formulation of docetaxel approved in the USA. The firm is seeking novel products for potential in-licensing and partnering opportunities to strengthen their current pipeline. In addition, the firm is unveiling a new initiative through which the company will provide equity investment to early-stage technologies for which the firm could help leverage clinical development. The size of investment will largely depend on the company’s stage of development, but the company is open to investing up to $5M in initial investment. The firm is seeking global opportunities.

The firm’s business is centered on 3 main indications: CNS, oncology, and pain management. With the new early-stage investment initiative, the firm will focus on topical pain, CNS, and dermatology.

The firm is most interested in new NCEs that can be in integrated with topical delivery technologies, as well as existing chemical entities that have applicability in patch and topical applications. The firm will consider technologies as early as in development/pre-clinical.

The firm has no specific management team requirements. The firm has a development and regulatory team that can help companies with advancing towards FDA approval as well as Asian market entry, particularly Japan. Because the firm has many resources and support to offer to early-stage companies, experienced management team and successful track record would be a plus, but not a requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a Toronto-based venture capital firm that was founded in 2016. The firm invests out of its second fund, which was initially closed in October 2020 at USD 150 million. Among the 150 million, the firm manages to invest 100 million directly in companies while the other 50 million will invest in funds. The firm focuses on investments in three main sectors: Biopharmaceutical, Healthcare Platform & Services, and Technology (i.e., SAAS, Fintech). The firm provides initial investments at USD 3-5 million, and it will also reserve a further amount for follow-on financing and supports the startups in strategic partnerships. The firm is interested in pre-clinical to clinical-stage biotech companies. The firm invests primarily in North America but also opens to invest in Europe or China.

The firm is looking for new opportunities in the life science space, including therapeutics, diagnostics, and healthcare platforms. The firm’s investments to date have included companies developing in cell therapy, oncology, neuroscience, and drug-discovery platform. The firm is opportunistic in terms of sector, subsectors, and indications. The firm will also consider orphan drugs. Within medical devices and digital health, the firm will only consider companies that already have a USD 10 million minimum revenue. The firm will only co-invest and will prefer to co-invest with well-known lead investors.

The firm does not have specific requirements on companies or management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The corporate venture of a publicly listed pharmaceutical group in Asia has successfully invested and established 7 IPO companies in Taiwan and Hong Kong. The firm now focuses on strategic investments which can synergize with its portfolio companies or future business. The firm is open to consider investment opportunities globally, and is willing to help overseas portfolio companies enter into Asia through licensing or joint venture activities. Typical allocation size can range from US$3-20 million.

The firm is investing strategically in selected sectors. Within therapeutics, the firm considers in companies with technology platforms in cell therapy, RNA therapies, bispecific and ADC drugs.  Investment stage can range from preclinical to early clinical stage.  The firm is also interested in investing in early stage CDMO companies in the areas above.

The firm is looking for experienced management teams with proven track records. The firm typically requests a board seat in its portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The investment division of a publicly traded biotech company is solely dedicated to the identification and success of early-stage, biotech start-ups for the company’s incubation and investment platforms. The company’s commitment is to operate a collaborative platform for innovative biotech companies from around the world, and for anyone aiming to develop an idea with transformative or strong potential.

The investment division firm invests globally in biotech innovation with novel solutions to unmet medical needs across multiple therapeutic areas. Leveraging the parent company’s experience and technical advantages in the field of novel drug R&D, the firm provides both cash and in-kind services (EFS) for their investment. Additionally, based on the need, the firm also offers value-added services in operation and logistic support, BD and Financing assistance, etc. to accelerate the growth of its portfolio companies. The firm can allocate from $500,000 to $5,000,000 of equity capital or convertible notes in seed or Series A.

The firm focuses on novel, preclinical therapeutics and is agnostic to indication, modality and geography. The firm is currently most interested in small molecule first-in-class drugs but is open to considering all drug types. For therapeutics, the firm is open to invest from super early-stage to pre-clinical stage. The firm will not invest in Diagnostics, Medical Devices, or Healthcare IT companies.

The firm does not have specific requirements for companies or management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based Life Sciences investment firm typically allocates up to $4M in projects. With follow-on allocations, the total investment can reach up to $10M per company. The firm takes a mid-to-long-term investment approach and often syndicates with major US venture capital firms, but it can also lead a financing round. The firm is currently seeking new opportunities in the US and Canada, and Western Europe.

The firm puts 70% focus on therapeutics and 30% on medical devices and diagnostics. In therapeutics, the firm prefers late-stage assets with human proof of concept and blockbuster potential, while it also has a minor interest in early-stage breakthrough science with strong management teams. In medical devices, the firm seeks to provide growth funding in de-risked medical devices and diagnostics in final approval steps, launch and international marketing efforts. The firm considers both single assets and platform technologies. The firm’s investment strategy is strictly patient-centric. Lab equipment, health IT, and biosimilars/generics are not of interest.

The firm focuses on five key disease areas: oncology, cardiovascular, anti-infectives, CNS/pain, and women’s health. In oncology, the firm seeks therapies with novel mechanisms of action and delivery, human data and signs of efficacy, and it also considers new generation diagnostics technologies. In cardiovascular diseases, the firm seeks life-saving therapies and technologies with strong human data. In anti-infectives, the firm is considering pre-clinical assets managed by serial entrepreneurs. In CNS, the firm seeks therapies with human proof-of-concept and clear mechanism of action. In women’s health, the firm seeks a wide range of therapies and technologies at all stages, which predominantly help women give birth to healthy children.

The firm is looking for high-caliber serial entrepreneurs with unmatched track-record of success and strong credibility. The firm typically takes a board seat in the companies it invests in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2020 and based in the West Coast USA is seeking opportunities in the medical devices, diagnostics, and digital health sectors of life sciences with its first fund. The firm is looking to engage in Seed to Series A financing rounds with initial check sizes between $4-8M. The firm will also make sub $1M investments in some cases, and will consider convertible notes for these checks. The firm will consider opportunities globally.

The firm is interested in early-stage opportunities in medical devices, diagnostics, and digital health sectors but does not invest in therapeutics. The firm is overall opportunistic and will consider various subsectors and indications. The firm is open to all 3 classes of medical devices.

The firm is open to all types of management teams, however clinical experience in the management team is a plus. The firm typically leads investments will seek a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.